Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Issue 6 (8th August 2020)

• Record Type: Journal Article
• Authors: Iborra, Marisa; Beltrán, Belén; Fernández‐Clotet, Agnes; Iglesias‐Flores, Eva; Navarro, Pablo; Rivero, Montserrat; Gutiérrez, Ana; Sierra‐Ausin, Mónica; Mesonero, Francisco; Ferreiro‐Iglesias, Rocío; Hinojosa, Joaquín; Calvet, Xavier; Sicilia, Beatriz; González‐Muñoza, Carlos; Antolín, Beatriz; González‐Vivo, María; Carbajo, Ana Y.; García‐López, Santiago; Martín‐Cardona, Albert; Surís, Gerard; Martin‐Arranz, María Dolores; de Francisco, Ruth; Cañete, Fiorella; Domènech, Eugeni; Nos, Pilar
• Other Names: Taxonera C. investigator.; Gomollón F. investigator.; Lorente R. investigator.; Rodríguez‐Lago I. investigator.; Forés‐Bosch A. investigator.; Bernardos E. investigator.; Ramos L. investigator.; Delgado‐Guillena P. investigator.; Hernández A. investigator.; Van Domselaar M. investigator.; Hervás D. investigator.; Casas‐Deza D. investigator.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 52:Issue 6(2020)
• Page Start: 1017
• Page End: 1030
• Publication Date: 2020-08-08
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.15958
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: Data on the long‐term administration of ustekinumab in recommended doses are limited. Aim: To assess the real‐world, long‐term effectiveness of ustekinumab in refractory Crohn's disease (CD). Methods: Multi‐centre study of CD patients starting ustekinumab at the recommended dose, followed for 1 year. Values for the Harvey‐Bradshaw Index (HBI), endoscopic activity, C‐reactive protein (CRP), and faecal calprotectin (FC) were recorded at baseline and at weeks 26 and 52. Demographic and clinical data, previous treatments, adverse events (AEs) and hospitalisations were documented. Potential predictors of remission were examined. Results: A total of 407 patients were analysed. The initial maintenance dose of 90 mg SC was administered every 12, 8 and 4 weeks in 56 (14%), 347 (85%) and 4 (1%) patients, respectively. After 52 weeks, treatment was discontinued in 112 patients (27.5%). At baseline, 295 (72%) had an HBI >4 points. Of these, 169 (57%) and 190 (64%) achieved clinical remission at weeks 26 and 52, respectively. FC levels returned to normal in 44% and 54% of patients at weeks 26 and 52, and CRP returned to normal in 36% and 37% of patients at weeks 26 and 52, respectively. AEs were recorded in 60 patients. The use of fewer previous anti‐TNFα agents and ileal localisation were associated with clinical remission, and endoscopic severity was associated with poor response. No factors correlated with endoscopic remission. Conclusion: After 52 weeks, ustekinumab demonstrated effectiveness in inducing clinical and endoscopic remission in patients with refractory CD.